Pavonine's 2026 Q1 Performance Weak: Sales Decline and Operating Profit Plunge... Shareholder Return Policy Continues

Consolidated Q1 2026 sales of KRW 31.8 billion (-9.9% YoY), operating profit of KRW 90 million (down KRW 900 million YoY), and net loss of KRW 312 million.
Consolidated debt ratio increased to 121.4% (from 106.2% at year-end), with higher interest costs and derivative valuation loss of KRW 970 million.
Recognized impairment of approximately KRW 6.6 billion, including 100% allowance for related party loans and equity investments.
Continued shareholder returns: acquired 324,087 treasury shares (new trust contract of KRW 1 billion) and paid dividends of KRW 906 million.
Pursuing medium-to-long-term growth through increased production at overseas subsidiaries (Vietnam, US, Mexico) and new medical device business.

ADVERTISEMENT (250px+)